B A S E C A R E
Focused on Reproductive Medicine! Professor Xu Yanwen was Specially Invited by Basecare Satellite Meeting to Share "PGT Strategies for Balanced Chromosome Structural Abnormalities"
September 17, 2021 · Guangzhou
On September 17, 2021, the 11th Academic Conference on Reproductive Medicine of Guangdong Medical Association was held in Sofitel Guangzhou Sunrich. The theme of the meeting was “Quality control of assisted reproduction”. Many well-known experts and scholars in the industry will hold wonderful academic exchanges on hot and difficult issues and basic research progress in assisted reproductive technology, bringing us a feast in reproductive medicine.

On September 17, 2021, the 11th Academic Conference on Reproductive Medicine of Guangdong Medical Association was held in Sofitel Guangzhou Sunrich. The theme of the meeting was “Quality control of assisted reproduction”. Many well-known experts and scholars in the industry will hold wonderful academic exchanges on hot and difficult issues and basic research progress in assisted reproductive technology, bringing us a feast in reproductive medicine.

On the first day of the meeting, Basecare Satellite Meeting specially invited Professor Xu Yanwen, Deputy Director of the Reproductive Medicine Branch of Guangdong Medical Association and Director of the Center for Reproductive Medicine of the First Affiliated Hospital, Sun Yat-sen University, to give a wonderful speech on "PGT strategies for balanced chromosome structural abnormalities". The meeting was presided over by Professor Zhou Canquan, director of the Reproductive Medicine Branch of Guangdong Medical Association and vice president of the First Affiliated Hospital, Sun Yat-sen University.


On the theme of "PGT strategies for balanced chromosome structural abnormalities ", Professor Xu introduced the clinical treatment options and the latest PGT strategies for chromosome structural abnormalities at the Basecare Satellite Meeting. Professor Xu said that compared with the conventional PGT-SR, PGH was able to conduct haplotype linkage analysis at the genome-wide level and avoid finding the precise location of the breaking point. Moreover, for patients and doctors, the haplotype could be constructed through the family, and healthy embryo with normal karyotype could be distinguished from translocation-carrying embryo when there was only one embryo available.


Later, Professor Xu shared two cases of successful blocking of balanced translocation and inversion in familial transmission by PGH, summarized advantages of PGH and made an outlook on the development direction of PGT. She said that the technical advantages of PGH lay in the aneuploidy screening of 23 pairs of chromosomes at one time, and the blocking of the structural variation of chromosomes and single-gene genetic diseases. Therefore, it was universal. Haplotype analysis of the whole genome can indicate the risk of homologous recombination, and was a clinical solution more suitable for the Chinese. In addition, Director Xu also emphasized that the integrated and universal PGT platform (PGT-One) would be the development direction of PGT, and more research would be done in this field in the future. In a high-level academic article on PGH published in July in the international authoritative journal Clinical and Translational Medicine (IF = 11.492), the research project used a customized high-density gene chip for genome-wide SNP genotyping of core families and embryonic cells. The chip has more than 30,000 customized high-frequency SNP loci for the Chinese population, making it more suitable for the Chinese.
PGT can block the genetic channels of some familial hereditary diseases from the source for couples who explicitly carry severe pathogenic genes or have an unexplained history of bad pregnancy. PGH is a breakthrough upgrade of the PGD/PGS, which can successfully block the transmission of reciprocal translocation in the family, realize the accurate screening of embryos, and bring hope to more families.
Basecare, as the leader in assisted reproduction in NGS, has created PGD/PGS and segment markets in China. The PGS kit independently developed by Basecare is the first PGD/PGS kit approved by the National Medical Products Administration. PGD and PGH kits are expected to be registered and approved in 2022 and 2024 respectively.
Basecare is committed to leading the development of assisted reproductive industry, and has been closely monitoring the academic trends and research progress in assisted reproduction at home and abroad. The 11th Academic Conference on Reproductive Medicine of Guangdong Medical Association will last for three days. We invite you to witness together!